TATimothy Adegoke

Timothy Adegoke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy Adegoke has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Joshua Ryan Smith

    Vanderbilt University Medical Center

    5 shared publications
  • Rafael Tamargo

    Division of General Psychiatry, Department of Psychiatry and Behavioral Sciences Vanderbilt University Medical Center at Village of Vanderbilt Nashville Tennessee USA

    4 shared publications
  • Courtney Hamilton

    Division of General Psychiatry, Department of Psychiatry and Behavioral Sciences; Vanderbilt University Medical Center at Village of Vanderbilt, 1500 21st Avenue South, Suite 2200, Nashville, Tennessee, 37212

    3 shared publications
  • James Luccarelli

    Department of Psychiatry Harvard Medical School Boston Massachusetts USA

    3 shared publications
  • Jo Ellen Wilson

    Division of General Psychiatry, Department of Psychiatry and Behavioral Sciences; Vanderbilt University Medical Center at Village of Vanderbilt, 1500 21st Avenue South, Suite 2200, Nashville, Tennessee, 37212

    3 shared publications
  • Sarah Marler

    Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences; Vanderbilt University Medical Center at Village of Vanderbilt, 1500 21st Avenue South, Suite 2200, Nashville, Tennessee, 37212

    3 shared publications

Latest Publications

  • Open Access

    Catatonic Features That May Be Mistaken for Worsening Autism Show Treatment-Associated Improvement: Implications for Later Regression

    by Joshua Ryan Smith, Maria Bonnee, Sarah Marler, Seri Lim, D. Catherine Fuchs, Rafael Tamargo, Isaac Baldwin, Christopher Maley, Ashley VanHaverbeck, Courtney Hamilton, et al.

    Catatonia in autistic individuals may resemble worsening autism yet represent a potentially treatable departure from baseline functioning. We compared item-level catatonic signs in autistic and non-autistic patients and evaluated treatment-associated change during electroconvulsive therapy (ECT). This single-center observational cohort included patients with catatonia who received ECT from May 2022 through April 2026. The 23-item Bush-Francis Catatonia Rating Scale (BFCRS) was assessed longitudinally. Pretreatment BFCRS data were available for 104 patients, including 41 autistic and 63 non-autistic patients, with 993 near-complete repeated assessments available. Pretreatment item presence was modeled using a three-level clinical-group variable with adjustment for age, biologic sex, and calendar year. Compared with non-autistic patients, patients with autism and intellectual disability had higher adjusted odds of eight activated, repetitive, or behaviorally dysregulated signs and lower odds of immobility/stupor. Among 96 patients with paired first and last eligible BFCRS assessments, multiple items improved in both cohorts. Generalized estimating equations demonstrated longitudinal declines in total BFCRS scores and multiple psychomotor-domain scores, with no clinical-group-by-time interaction surviving false-discovery rate correction in unrestricted or 30-, 60-, 90-, and 180-day models. Autism-specific Kanner analyses identified significant fixed-endpoint improvement in seven severity items after false-discovery rate correction, six of which were reproduced longitudinally. Catatonia in autistic patients with intellectual disability was characterized by a phenotype that may resemble worsening autism during later regression, and many constituent signs demonstrated treatment-associated improvement during ECT. Lay Summary: Some autistic individuals experience later behavioral, motor, or functional regression, which may have potentially treatable causes such as catatonia. In this study, patients with autism and intellectual disability were more likely to show activated, repetitive, and behaviorally dysregulated catatonic features than non-autistic patients, and these features improved during treatment. Catatonia should be considered when an autistic person develops new or substantially worsening repetitive behavior, impulsivity, aggression, communication loss, reduced self-care, mobility changes, food refusal, or other departures from prior functioning.

  • Open Access

    Electroconvulsive Therapy for Catatonia in Autistic and Non‐Autistic Patients: An Observational Study on Course, Efficacy, Aggression, and Self‐Injury Outcomes

    by Joshua Ryan Smith, Maria Bonnee, Sarah Marler, Seri Lim, D. Catherine Fuchs, Rafael Tamargo, Isaac Baldwin, Christopher Maley, Ashley VanHaverbeck, Courtney Hamilton, et al.

    Catatonia occurs disproportionately in autistic individuals and may respond to electroconvulsive therapy (ECT), yet prior reports suggest greater treatment burden in this population. We compared longitudinal ECT utilization, safety, and clinical outcomes between autistic and non‐autistic patients with catatonia. This single‐center observational cohort included 110 patients treated from May 2022 through April 2026, comprising 43 autistic and 67 non‐autistic patients. Bush‐Francis Catatonia Rating Scale (BFCRS), Clinical Global Impression‐Improvement (CGI‐I), Clinical Global Impression‐Severity (CGI‐S), and Kanner Catatonia Severity and Examination scores were recorded across acute and maintenance treatment. Because the cohorts differed in age, biologic sex, and intellectual disability, treatment burden was evaluated using covariate‐adjusted, censoring‐aware models with a three‐level clinical‐group variable comprising non‐autism, autism with intellectual disability, and autism without intellectual disability. Autistic patients received more ECT sessions than non‐autistic patients (median, 35 vs. 14) over longer observed treatment courses (median, 342 vs. 97 days). After adjustment, this difference reflected longer retention in maintenance ECT rather than a higher treatment rate and was concentrated among autistic patients with intellectual disability (Cox hazard ratio, 0.21). Clinical improvement was observed in both cohorts: CGI‐I response occurred in 100.0% of autistic and 89.1% of non‐autistic patients, BFCRS reduction of at least 50% occurred in 76.9% and 75.4%, and CGI‐S improvement of at least 1 point occurred in 85.0% and 70.8%, respectively. Kanner total scores decreased significantly, and self‐injury prevalence declined from 42.9% to 17.1% among autistic patients. Combativeness improved in both cohorts, and documented adverse events were uncommon. ECT was associated with substantial clinical improvement in autistic and non‐autistic patients with catatonia. Autistic patients, particularly those with intellectual disability, experienced longer maintenance courses rather than more intensive treatment, underscoring the importance of sustained treatment access.


  • Open Access

    Use of Electroconvulsive Therapy for Catatonia in Down Syndrome Regression Disorder: A Systematic Review, Case Series, and Analysis

    by Seri Lim, Kaidi Kang, Elizabeth Oey, Stephanie Santoro, Catherine Franklin, James Luccarelli, Rafael Tamargo, Courtney Hamilton, Sarah Marler, Timothy Adegoke, et al.

    Purpose: Down syndrome regression disorder (DSRD) is a condition occurring in young people with Down syndrome. It is associated with functional decline, new onset psychopathology, and increased support needs. DSRD is often associated with catatonia, for which electroconvulsive therapy (ECT) is an effective treatment. However, there are scant studies to guide best practice in this area. Methods: We report a case series of 5 patients who have received ECT at Vanderbilt University Medical Center. A systematic review and analysis were conducted, combining this case series with previously reported data in the literature. Results: This analysis included data from 27 patients, 5 from the VUMC case series and a further 22 from 14 studies. Combining all patients from case series and the systematic review, there were 17 pre-ECT and 15 post-ECT Bush Francis Catatonia Rating Scale (BFCRS) scores reported from 7 sites/studies. The mean pre-ECT BFCRS score from all patients was 17.40 (SD = 5.72) and the mean post-ECT BFCRS score was 4.40 (SD = 5.26). A generalized estimating equations analysis revealed that there was a significant difference in the expected BFCRS score before and after receiving ECT treatment ( β = -13.00 with 95%, p < 0.001), suggesting that the ECT treatment had a significant effect on reducing the BFCRS scores. No severe adverse events were reported. Conclusion: ECT is associated with clinical improvement in patients with catatonia in the context of DSRD in this systematic review and analysis. More research is needed to provide a more robust evidence base.

  • Open Access

    Treat to Sedation: Managing Intravenous Placement for Electroconvulsive Therapy in Autism with Intellectual Disability and Hyperactive Catatonia

    by Aparna Srinivasan, James Luccarelli, Rafael Tamargo, Timothy Adegoke, Joshua R. Smith

    Purpose: Catatonia is a severe psychomotor and mood-related disorder, which can significantly impact the quality of life for autistic individuals. Often, electroconvulsive therapy (ECT) is required for treatment of catatonia in autism. However, hyperactive, impulsive, and aggressive symptoms are common in this subpopulation. Thus, pharmacologic agents are needed to assist in obtaining intravenous (IV) access and placement of necessary monitoring leads when ECT is pursued. Here we report six patients with autism and hyperactive catatonia who successfully and safely received intramuscular (IM) ketamine to obtain IV access for ECT while prescribed high-dose benzodiazepines for catatonia. Methods: Using SlicerDicer software found within Epic Systems electronic medical record, we conducted a single-site retrospective analysis. All patients had a diagnosis of autism, were treated for hyperactive catatonia with ECT, and required the use of ketamine for safe IV placement. Diagnoses of autism and catatonia were confirmed per the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders . Results: Six patients were identified. All patients met criteria for autism, intellectual disability, and catatonia. The patient’s ages ranged from 10 to 30 years, and all were prescribed high doses of benzodiazepines for treatment of catatonia, with a mean dose of 24 mg per day in lorazepam equivalents. The patients’ symptoms of hyperactive catatonia impaired the ability to obtain IV access. Thus, IM ketamine was received by all patients to facilitate this process. All patients were able to receive ECT. Conclusion: In all cases, IM ketamine was successfully used to obtain IV access and allow patients to receive ECT uneventfully. No serious adverse events were reported despite the coadministration of ketamine with high-dose benzodiazepines in this patient subpopulation.


  • Open Access

    Pathways and Barriers to Careers in Academic Clinical Cancer Prevention: a Qualitative Study

    by Melissa Y. Kok, Janelle C. Chavez, Pompeyo R. Quesada, Oluwapelumi T. Adegoke, Shine Chang

    National surveys document steady declines over time in interest in academic medicine and cancer prevention careers (Am J Prev Med 54(3):444–8, 2018). Through interviews with 16 academic cancer prevention physicians at one comprehensive cancer center, this study identifies motivations and barriers to physician careers in academic cancer prevention and proposes recommendations to increase recruitment. Participants reported that cancer prevention was vague to them early in training, impairing career exploration. Further, without role models and opportunities to learn about cancer prevention, many were ignorant of career options. Many had incorrect views about cancer prevention practice being mainly within the scope of primary care physicians, and some reported colleagues viewing the rigor of cancer prevention skeptically. However, all described notable experiences—in classes, with mentors, on research projects, or from encounters with patients, motivating them to pursue academic clinical cancer prevention regardless of challenges. Clearly, a lack of both information and guidance towards careers in clinical cancer prevention has been critical barriers to robust recruitment of physicians to the field and must be addressed urgently. Helping physicians earlier during training to both understand the value of prevention and cultivate their interests in it, particularly for clinical cancer prevention, would have widespread benefits.